MenopausePub Date : 2023-12-12DOI: 10.1097/gme.0000000000002296
Di Zhao, Qinghua Ma, Guopeng Li, Rui Qin, Yingtao Meng, Ping Li
{"title":"Treatment-induced menopause symptoms among women with breast cancer undergoing chemotherapy in China: a comparison to age- and menopause status-matched controls.","authors":"Di Zhao, Qinghua Ma, Guopeng Li, Rui Qin, Yingtao Meng, Ping Li","doi":"10.1097/gme.0000000000002296","DOIUrl":"https://doi.org/10.1097/gme.0000000000002296","url":null,"abstract":"Whether women with breast cancer experience more severe menopause symptoms than comparison women without a history of breast cancer diagnosis remains unclear. We aimed to investigate whether women with breast cancer undergoing chemotherapy experience more severe menopause symptoms than comparison women and explore various factors influencing menopause symptoms in women with breast cancer undergoing chemotherapy.","PeriodicalId":18404,"journal":{"name":"Menopause","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138691412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MenopausePub Date : 2023-10-31DOI: 10.1097/gme.0000000000002272
Alyssa N. Sheedy, Jean Wactawski-Wende, Kathleen M. Hovey, Michael J. LaMonte
{"title":"Discontinuation of hormone therapy and bone mineral density: does physical activity modify that relationship?","authors":"Alyssa N. Sheedy, Jean Wactawski-Wende, Kathleen M. Hovey, Michael J. LaMonte","doi":"10.1097/gme.0000000000002272","DOIUrl":"https://doi.org/10.1097/gme.0000000000002272","url":null,"abstract":"Abstract Objective Hormone therapy can positively impact bone mineral density after menopause. We explored bone mineral density change in postmenopausal women who discontinued hormone therapy after the Women's Health Initiative landmark 2002 trial results were published. We secondarily explored whether usual physical activity modified the results. Methods Postmenopausal women participating in the Buffalo OsteoPerio study with information on hip bone density, hormone therapy use, and self-reported physical activity at two time points (1997-2001; 2002-2007) were included (N = 961). Hormone therapy included three groups according to use at baseline and year 5 (non/non; current/non; current/current). Results At baseline (mean age, 65.9 years; SD, 6.7 years), 480 women were not using hormone therapy, while 481 were current users. Between the baseline and 5-year visits, 336 women using hormone therapy discontinued. Baseline total hip bone density was highest in current users. After 5 years, those who continued hormone therapy exhibited no bone loss; those who discontinued exhibited the greatest loss at the total hip of −0.021 gm/cm 2 . Women who never used hormone therapy exhibited some loss of −0.012 gm/cm 2 . Usual physical activity did not appreciably impact change in bone density in any group. Conclusions This prospective observational study explored the 5-year change in bone mineral density among older postmenopausal women after the landmark 2002 hormone therapy trial findings were released. We found bone density decreased in never-users and in women who discontinued use. Bone density was maintained in current users. Although usual physical activity did not mitigate bone loss, targeted physical activity regimens should be investigated.","PeriodicalId":18404,"journal":{"name":"Menopause","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135871232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MenopausePub Date : 2023-10-31DOI: 10.1097/gme.0000000000002271
Yufei Shen, Lucia Li, Hailong Wang, Yi Hu, Xi Deng, Xiaoling Lian, Yanlin Tan, Liling Liang, Yu Zhang, Wenqing Yang
{"title":"Triage method for endometrial biopsy in postmenopausal women: a multicenter retrospective cohort study","authors":"Yufei Shen, Lucia Li, Hailong Wang, Yi Hu, Xi Deng, Xiaoling Lian, Yanlin Tan, Liling Liang, Yu Zhang, Wenqing Yang","doi":"10.1097/gme.0000000000002271","DOIUrl":"https://doi.org/10.1097/gme.0000000000002271","url":null,"abstract":"Abstract Objective To identify the optimal triage procedure for endometrial biopsies in postmenopausal women. Methods The clinical information of 470 postmenopausal women with endometrial biopsy results and postmenopausal bleeding (PMB) and/or transvaginal ultrasonography (TVU) abnormalities were collected at the gynecology departments of four general hospitals from March 2021 to March 2022. In the validation cohort, 112 women with TVU abnormalities who underwent endometrial biopsy at Xiangya hospital between May 2022 and May 2023 were enrolled. The endpoint was the final diagnosis based on hysteroscopy reports and biopsy pathology results. The sensitivity, specificity, positive predictive value, and negative predictive value were compared among the three triage methods. A nomogram prediction model was developed and validated. Results Referring women with TVU abnormalities for endometrial biopsy identified 100% malignant/premalignant lesions despite low specificity (19.7%). Among women with measurable endometrial thickness (ET), we suggest that the ET cutoff value for biopsy referral should be ≥4 mm. The PMB (odds ratio [OR], 3.241; 95% confidence interval [CI], 1.073-9.789), diabetes (OR, 10.915; 95% CI, 3.389-35.156), and endometrial thickness (OR, 1.277; 95% CI, 1.156-1.409) were independent predictive factors for endometrial (pre)malignancy. A nomogram prediction model was constructed (area under curve [AUC] = 0.802, 95% CI: 0.715 to 0.889). The ideal cutoff point was 22.5, with a sensitivity of 100.0% and a specificity of 15.7%. The external validation achieved an AUC of 0.798 (95% CI, 0.685-0.911). Conclusions It was possible to refer all postmenopausal women with TVU abnormity (ET ≥ 4 mm or other abnormal findings) for endometrial biopsy. Among women with TVU abnormalities, a nomogram was constructed, and a score greater than 22.5 suggested the need for referral for endometrial biopsy, while a score less than 22.5 suggested that regular follow-up was required, further improving the triage procedure.","PeriodicalId":18404,"journal":{"name":"Menopause","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135869382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}